# Surrozen, Inc./DE (SRZN) · Edgar & Edgarette company card

> Surrozen (SRZN) saw revenue fall 67.4% in FY2025 to $3 million, operating margin -1211% against a -15.8% median for biological products, (no diagnostic substances), equity -190% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1824893 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SRZN) · [JSON](https://www.pops4.com/boards/company/SRZN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $3M |
| Revenue growth, 1 year | -67.4% |
| Revenue growth per year | — |
| Operating margin | -1210.6% (prior year -239.7%) |
| Net margin | -6960.8% |
| Operating cash flow | −$30M |
| Capital spending | $280,000 |
| Free cash flow | −$31M |
| Cash | $89M |
| Long-term debt | — |
| Total assets | $99M |
| Total equity | −$188M |
| Equity ÷ assets | -190.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -15.54 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -1210.6% in FY2025; revenue is hard to predict: its 80% range is ±53%

## Edgarette's reading

Exposure: revenue $3.5M (FY2025). Experience: revenue down 67.4% on the year; operating margin -1210.6%, down from -239.7%. Soundness: equity -190.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $930K and $3.0M next year (method v4.1: its own 1-year record of growth weighed at 0% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $858K to $3.3M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -1210.6% against a -15.8% median; growth -67.4% against 21.4%.

Range logged 2026-11-17, receipt 04ce3c7aebf8fe20, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-01-30 ([filing](https://www.sec.gov/Archives/edgar/data/1824893/000119312526031798/0001193125-26-031798-index.htm))

## Recent filings

- 8-K · filed 2026-11-16 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1824893/000119312526462191/0001193125-26-462191-index.htm)
- 10-Q · filed 2026-11-09 · [filing](https://www.sec.gov/Archives/edgar/data/1824893/000119312526453790/0001193125-26-453790-index.htm)
- 8-K · filed 2026-11-09 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1824893/000119312526453641/0001193125-26-453641-index.htm)
- 8-K · filed 2026-10-20 · 2.02 Results of Operations and Financial Condition; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/0001193125-26-426828-index.htm)
- 8-K · filed 2026-10-02 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/0001193125-26-411298-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1824893/000119312526338120/0001193125-26-338120-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001824893.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1824893

## Cite

POPS4, Edgar & Edgarette: Surrozen, Inc./DE (SRZN) company card, from the company's own SEC filings, accessed 2026-11-17, https://www.pops4.com/boards/company/SRZN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

